Company
Every investor coverage indicates participated in a round The University of Texas, MD Anderson Cancer Center raised.
Companies The University of Texas, MD Anderson Cancer Center acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming The University of Texas, MD Anderson Cancer Center. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ChemGenex Pharmaceuticals reports pre-clinical findings that omacetaxine destroys leukemic stem cells in chronic myeloid leukemia models, presented at the European Hematology Association congress, with collaborators in Glasgow and a US leukemia specialist.
ChemGenex reported Phase 2/3 trial results for omacetaxine in resistant CML patients at ASCO, with investigators suggesting it could become the first workable therapy for T315I-mutant patients; regulatory filing targeted for Q3.